Targets for the Induction of Protective Immunity Against Influenza A Viruses by Bodewes, Rogier et al.
Viruses 2010, 2, 166-188; doi:10.3390/v2010166 
 
viruses
ISSN 1999-4915 
www.mdpi.com/journal/viruses 
Review 
Targets for the Induction of Protective Immunity Against 
Influenza A Viruses 
Rogier Bodewes, Albert D.M.E. Osterhaus and Guus F. Rimmelzwaan *  
Department of Virology, ErasmusMC, Dr. Molewaterplein 50, 3015 GE, Rotterdam, The Netherlands; 
E-Mails: r.bodewes@erasmusmc.nl (R.B.); a.osterhaus@erasmusmc.nl (A.D.M.E.O.)  
*  Author to whom correspondence should be addressed; E-Mail: g.rimmelzwaan@erasmusmc.nl;  
Tel.: +31 10 704 4243; Fax: +31 10 7044760. 
Received: 31 August 2009; in revised form: 4 January 2010 / Accepted: 13 January 2010 /  
Published: 14 January 2010 
 
Abstract: The current pandemic caused by the new influenza A(H1N1) virus of swine 
origin and the current pandemic threat caused by the highly pathogenic avian influenza A 
viruses of the H5N1 subtype have renewed the interest in the development of vaccines that 
can induce broad protective immunity. Preferably, vaccines not only provide protection 
against the homologous strains, but also against heterologous strains, even of another 
subtype. Here we describe viral targets and the arms of the immune response involved in 
protection against influenza virus infections such as antibodies directed against the 
hemagglutinin, neuraminidase and the M2 protein and cellular immune responses directed 
against the internal viral proteins. 
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1. Introduction  
Influenza epidemics are the cause of three to five million cases of severe illness every year and 
approximately 250,000 to 500,000 of these cases are fatal. Epidemics occur during autumn and winter 
in regions with a temperate climate, while in some tropical countries influenza viruses circulate 
throughout the year with one or two peaks during the rainy seasons [1]. Mainly the young, elderly and 
subjects with chronical medical conditions are at risk for developing severe disease after seasonal 
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influenza virus infection. Therefore, the World Health Organization (WHO) recommends annual 
vaccination of these subjects, which is an effective measure to protect them against influenza and its 
complications [1].  
The genome of influenza viruses consists of eight gene segments of negative sense RNA and since 
these viruses lack proofreading activity during their replication, they can accumulate mutations under 
selective pressure. This way, influenza viruses can escape from recognition by virus-neutralizing 
antibodies that are induced by previous infections or vaccinations. Indeed, the highest degree of 
variations is observed in the antigenic sites of the hemagglutinin against which virus neutralizing 
antibodies are directed [2,3]. As a result of this antigenic variation, the influenza vaccine that contains 
components of three currently circulating influenza viruses (A/H1N1, A/H3N2 and B viruses) has to 
be updated almost every year to match the circulating strains. Since the selection of the vaccine strains 
and vaccine production has to be carried out before the start of the influenza season, there is some 
uncertainty in this prediction and mismatches do occur occasionally. In addition to the small gradual 
antigenic changes of currently circulating influenza virus strains (antigenic drift), occasionally new 
influenza viruses of novel subtypes are introduced into the human population. The subtypes of these 
viruses are defined by the envelope glycoproteins of these viruses, the hemagglutinin (HA) and the 
neuraminidase (NA). Wild aquatic birds are the natural reservoir of all subtypes of influenza from 
which there is spillover to other (domestic) birds and mammalian species, like pigs, horses and men 
[4]. Because antibodies against these viruses are virtually absent in the human population, these 
viruses may cause pandemic outbreaks of influenza affecting a substantial proportion of the human 
population. In the last century, three pandemics occurred, which were caused by influenza A viruses of 
the H1N1, H2N2 and H3N2 subtypes.  
Recently, influenza A viruses of swine origin have caused the first pandemic of the 21
st century [5]. 
These new pandemic viruses are the result of the exchange of gene segments originating from human, 
classical swine and avian-like influenza viruses and have emerged and spread worldwide within a few 
months [6,7]. As of 30 December 2009 at least 12220 people have been killed due to infection with the 
influenza A/H1N1(2009) virus [8]. Since not all fatal cases are reported, the real number of fatal cases 
is most likely much higher.  
In contrast to the efficient human-to-human transmission and the rapid spread of the new influenza 
A/H1N1 viruses, the highly pathogenic avian influenza A viruses of the H5N1 subtype, first detected 
in humans in 1997 [9,10] are transmitted from human-to-human inefficiently so far, although clusters 
of human-to-human transmission have been reported [11,12]. However, of the 438 human cases that 
have been reported since 2003, 60% had a fatal outcome [13] and therefore it is feared that these 
viruses may adapt and become pandemic in the future. For example, mutations in the receptor binding 
site may allow these viruses to use the receptor present on most cells of the human tracheal and 
bronchial epithelium (sialic acid- -2,6-Gal-terminated saccharides;  -2,6-SA) in addition to the avian 
receptor ( -2,3-SA), which is a prerequisite for replication in the upper respiratory tract and efficient 
transmission between humans [14].  
In addition to avian A/H5N1 viruses and the new A/H1N1 viruses of swine origin, also influenza A 
viruses of other subtypes have crossed the species barrier and have infected humans recently. In 2000, 
an avian influenza A/H9N2 virus infected two children in Hong Kong causing only mild disease [15] Viruses 2010, 2                                       
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whereas in 2003, during an outbreak of highly pathogenic avian influenza A/H7N7 in poultry in The 
Netherlands 89 humans were infected of which one died [16]. 
Because of the continuous threat of influenza pandemics and epidemics, there is considerable 
interest in the development of vaccines that can induce protective immunity against these viruses. 
Since influenza viruses are “moving targets”, ideally new vaccines should induce broad protective 
immune responses against multiple subtypes of influenza A viruses. In the present review, we discuss 
influenza virus proteins as targets for the induction of protective immunity against these viruses with 
emphasis on those proteins that are targets for the induction of heterosubtypic immunity. 
2. Influenza viruses and their proteins  
Influenza A viruses are enveloped single stranded negative sense RNA viruses with a genome 
consisting of eight gene segments encoding eleven different proteins. These eight RNA segments are 
independently encapsidated by the nucleoprotein (NP) and associated with the polymerase proteins 
PB1, PB2 and PA, which together form the ribonucleoprotein complex [17]. The polymerase proteins 
are responsible for replication and transcription of vRNA and mRNA respectively [18]. The matrix 
protein M1 functions as a spacer between the RNP complexes and the viral envelope and interacts with 
both. The viral envelope is derived from the host cell membrane. Two major surface glycoproteins 
(HA and NA) are inserted and protrude from the viral envelope. The HA is the receptor binding 
protein, facilitating attachment of the virus particle to the host cell. The HA is synthesized as a 
precursor polypeptide HA0 which requires proteolytic cleavage into HA1 and HA2 subunits before it 
becomes functional and virus particles can infect cells. The HA1 subunit contains the receptor-binding 
pocket and the relatively conserved HA2 unit constitutes the stem region containing the fusion peptide. 
This fusion peptide plays an important role in pH-dependent fusion of the viral envelope with the 
endosomal vesicle.  
By acting as a receptor-destroying enzyme, the NA plays an important role in the virus replication 
cycle after budding of new viruses from the infected cell. NA cleaves sialic acid residues, which 
promotes release of newly produced virus particles from the infected cell.  
The minor envelope protein, M2, is the result of alternative splicing of mRNA encoding M1. It 
functions as an ion channel and facilitates the influx of H+ ions into the virus particle, resulting in 
uncoating of the RNP complex and their release into the cytoplasm of the cell, which is a crucial step 
in the replication cycle. M2 is the target for the antiviral drug amantadine. 
Two non-structural (NS) proteins are also expressed in the infected cell, NS1 and NS2. NS1 is a 
multifunctional protein and is known for antagonizing the host cell IFN production and its activity 
[18]. NS2 is involved in nuclear transport of RNP complexes. Recently, the eleventh viral protein was 
identified which is transcribed from an alternative reading frame of PB1 (PB1-F2) [19]. Most likely, 
this protein plays a role in promoting apoptosis of the infected cell. 
As for other virus infections, influenza viral proteins are degraded in the cytosol of the infected cell 
by the proteasome into peptides. These peptides are transported to the endoplasmatic reticulum where 
they can bind to MHC class I molecules. The MHC class I peptide complexes are subsequently 
transported to the surface of the infected cells where they can be recognized by virus specific CD8+ T 
cells (see below). Viruses 2010, 2                                       
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3. Immunity to influenza viruses  
Infection with influenza virus does not induce lifelong protective immunity against influenza 
infection in humans, even not against infection with the same subtype. The main reason for this is that 
influenza A viruses continue to circulate as antigenic drift variants, that have accumulated mutations in 
antigenic sites of the HA molecule that are recognized by virus neutralizing antibodies. However, the 
induction of antibodies of the proper specificity will afford strain-specific protection and this strain-
specific immunity can be very long lasting. Recently, it was demonstrated that humoral immunity 
against the 1918 influenza A/H1N1 virus was still present in some individuals that were born before 
1918, nearly 90 years after the start of the pandemic [20]. In addition, a substantial proportion of the 
elderly have potentially protective antibody titers against the influenza A/H1N1(2009) virus, most 
likely as a result of historical exposure to a similar virus [21]. 
Since subtypes of the influenza viruses are defined by the absence of mutual cross-reactivity of 
subtype specific antibodies [22], antibodies to one subtype will not afford protection against infection 
with an influenza virus of another subtype. However, it has been demonstrated that infection with an 
influenza A virus can induce a certain degree of protective immunity against infection with an 
influenza A virus of another subtype, although infection cannot be prevented [23]. This so-called 
heterosubtypic immunity was first described more than four decades ago [24]. For example, infection 
of mice with influenza A/H3N2 or A/H9N2 viruses ameliorated the clinical course of infection with 
highly pathogenic influenza A/H5N1 viruses considerably and reduced mortality rates [25,26]. 
Heterosubtypic immunity induced by infection has shown to be long-lasting (18 months) in the ferret 
model, which is the gold standard model for human influenza A virus infections [27]. The 
immunologic basis underlying heterosubtypic immunity has been the topic of numerous studies [23]. 
Experiments in multiple knock-out and transgenic mouse models have shown that virus-specific CD4+ 
T cells (T helper cells), CD8+ Cytotoxic T cells (CTL), mucosal antibodies (IgA) and B cells can 
contribute to heterosubtypic immunity [28-33]. Especially cell-mediated immune responses directed to 
conserved proteins of influenza A viruses are believed to play an important role.  
There is also evidence that infection with an influenza A virus can induce heterosubtypic immunity 
in humans [34-36]. For example, individuals that had experienced an infection with an influenza 
A/H1N1 virus before 1957 less likely developed flu during the H2N2 pandemic of 1957 [35]. 
4. Influenza A virus vaccines 
Most influenza virus vaccines that are currently used against seasonal influenza viruses and against 
the influenza A/H1N1(2009) virus are prepared by infecting embryonated chicken eggs with influenza 
virus vaccine strains. Subsequently allantoic fluids of infected eggs are harvested and the egg-derived 
virus is purified. Depending on the vaccine manufacturer, influenza viruses are inactivated with 
formaldehyde or ß-propiolactone to prepare a whole inactivated influenza virus vaccine or treated with 
a detergent to prepare a split or subunit influenza vaccine. Subunit vaccines are, after treatment with a 
detergent, further purified to remove all viral proteins and lipids except the HA and NA. To obtain 
high yields of influenza virus antigens after infecting chicken eggs, reassortant viruses are prepared by 
infecting embryonated chicken eggs simultaneously with a selected epidemic strain and an egg-Viruses 2010, 2                                       
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adapted laboratory strain, typically influenza A virus A/PR/8/34. Reassortant viruses that carry the HA 
and NA of the epidemic strain and that grow to high virus titers are selected and used as vaccine strain.  
Influenza virus vaccines can also be prepared by growing viruses in cell cultures or by using live 
attenuated influenza viruses. Cell culture-derived influenza virus vaccines are prepared essentially 
with the same procedure that is used to prepare egg-derived influenza virus vaccines, except that cells 
are used to propagate viruses. Live attenuated viruses are typically attenuated by adapting viruses to 
replicate at lower temperatures. Cold-adapted vaccine strains are subsequently prepared by 
reassortment with selected epidemic strains to ensure that the vaccine strains contain the proper HA 
and NA.  
Currently, alternative formulations and methods to prepare influenza virus vaccines are in various 
stages of development or already licensed. Examples are the production of vaccine strains by reverse 
genetics, the use of virosomes and virus-like particles and the expression of viral genes in recombinant 
baculoviruses or modified vaccinia viruses [37-41]. 
5. Viral targets for the induction of humoral immunity  
5.1. Hemagglutinin 
It has been well documented that the induction of HA specific antibodies correlate with protection 
against infection, provided that they have the proper strain-specificity [42]. These antibodies can 
neutralize the virus by binding to the region responsible for binding of the HA molecule to its receptor 
on host cells. This way, binding of virus to the host cell is prevented efficiently. Therefore the 
induction of HA antibodies that block receptor binding is used as a correlate of vaccine efficacy and 
vaccines are registered every year when they fulfill the minimal EMEA/FDA requirements according 
to the serological outcome of vaccination and potency of the vaccine (>15μg HA per vaccine strain). 
To this end, pre- and post vaccination sera are tested in the hemagglutination inhibition (HI) assay to 
assess the HI antibody seroconversion rates and the proportion of study subjects that obtained 
protective antibody levels. Antibody titers >40 in this HI assay are considered protective [42]. 
As outlined above, HA-specific antibodies to one subtype per definition will not cross-react with 
another. Sixteen subtypes of HA have been identified so far [43]. These subtypes are discriminated by 
double immunodiffusion assays using hyperimmune animal sera, confirming the mutual lack of cross-
reactivity between subtypes [22]. Furthermore, the structure of antigenic sites vary among different 
subtypes, as it was demonstrated that the structures of antigenic sites of H5 [44,45], H9 [46] were 
different from H1, H2 and H3 subtypes. Five antigenic sites of the H3 subtype have been identified, 
mainly in the globular head region [47-50]. Antigenic sites of H1 and H2 have also been characterized 
by the identification of amino acid substitutions in the HA sequence [51,52].  
Although antisera against one subtype do not cross-react with an other subtype, monoclonal 
antibodies have been described that do cross-react with various HA subtypes [53,54]. Passive 
immunization with these HA-specific antibodies afforded protection against viruses of various 
subtypes [55-62]. More recently, a monoclonal antibody was generated that recognizes a common 
epitope on the globular head region of HA. This antibody inhibited virus binding to host-cell receptors 
and when administered to mice, protected against challenge infection with influenza viruses of the H1 
and H3 subtypes [63]. Viruses 2010, 2                                       
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Using combinational libraries built from B cells obtained from subjects recently vaccinated against 
seasonal influenza, a number of human antibodies were derived that displayed an unexpected broad 
reactivity with various subtypes of influenza virus, which were neutralized by these antibodies. The 
binding region of these monoclonal antibodies is located in the conserved region of the HA stem 
domain. Their prophylactic and therapeutic efficacy against H5N1 and H1N1 influenza A viruses was 
demonstrated in mice [64]. Thus, although the serum antibody response to influenza virus HA 
molecules is subtype specific and even specific for individual variants within a subtype without cross-
reactivity with other strains, some conserved epitopes do exist and antibodies against these epitopes 
may exert biological activity. It is unclear whether the antibody response to these conserved epitopes 
contributes to heterosubtypic immunity. It was demonstrated that mice intranasally vaccinated with an 
influenza A/H3N2 vaccine adjuvanted with an E. coli heat labile enterotoxin were protected against 
infection with an influenza A/H5N1 virus [65]. Using B-cell deficient IgH-6-/- and B2m mice, it was 
demonstrated that this type of protection was dependent on the presence of B-cells, most likely at the 
site of infection. 
5.2. Neuraminidase 
The NA plays an important role in the virus replication cycle after budding of new viruses from the 
infected cell, by cleaving sialic acid molecules from cellular receptors on infected cells and newly 
produced virus particles, thus acting as a receptor-destroying enzyme. It has been demonstrated that 
antibodies against NA can inhibit its enzymatic activity [66-68]. Since this biological activity only can 
take place in a late step of the virus replication cycle, NA specific antibodies cannot prevent infection, 
like HA-specific antibodies [69-71]. However, the induction of NA-specific antibodies can markedly 
reduce virus replication by inhibiting the release of newly produced virus particles and shorten the 
severity and duration of illness [69,72-74]. Furthermore, it has been demonstrated that NA can play a 
role during the entry stage of influenza virus infection of human airway epithelial cells in vitro. This 
suggests that antibodies that bind to NA have an impact during an early stage of the infection cycle. 
However, the exact mode of action of this function of NA and the relative contribution of antibodies 
that blocks this function to protective immunity is unknown [75].  
NA-specific antibody responses have been detected in humans after vaccination with inactivated 
vaccines [66,76], which may also contribute to the clinical vaccine effectiveness of influenza vaccines. 
Although NA and HA are both immunogenic, intact influenza viruses induce a stronger antibody 
response to the HA than to NA as result of antigenic competition [67,68,77-79].  
Recently, it was demonstrated that vaccination of mice with a DNA vaccine from which the NA 
gene of a contemporary human H1N1 strain was expressed conferred protection against infection with 
influenza viruses of both the H1N1 and H5N1 subtype [80]. Furthermore, it was shown that in human 
sera, antibodies against the NA of human influenza viruses were present that also inhibited the 
enzymatic activity of NA of the N1 subtype derived from avian influenza A viruses [80]. This data 
indicated that induction of NA in vaccines may broaden their protective potential against viruses with 
unrelated HA subtypes.  Viruses 2010, 2                                       
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5.3. M2 protein 
The M2 protein is a membrane protein with ion channel activity and plays an important role in the 
virus replication cycle. Compared to HA and NA, it is a minor antigen on mature virions, however its 
expression in virus-infected cells can be readily detected [81-83]. The first evidence that antibodies to 
the M2 protein have antiviral activity was demonstrated in vitro using a mouse monoclonal antibody 
directed to M2 [84,85]. Administration of M2-specific monoclonal antibodies intravenously to 
recipient mice inhibited influenza A virus replication in infected animals. Therefore, M2 was 
considered a promising target for the induction of protective immunity against influenza A viruses. 
Since this protein is very conserved, even between different subtypes of influenza A virus originating 
from various animal species, it was also considered as a vaccine candidate that could induce broadly 
protective antibody responses [86,87]. Indeed, hyperimmunization with vaccines based on the M2 
protein or its 23 amino acid ectodomain (M2e) induced antibodies that protected experimental animals 
against infection with viruses of various subtypes (for review see [88]). To increase the 
immunogenicity of M2e it was coupled to carriers such as the Hepatitis B virus like particles [87-90]. 
The mode of action of vaccine-induced M2e is probably not direct neutralization of virus, but involves 
antibody dependent cellular cytotoxicity by NK cells which contribute to the elimination of virus-
infected cells [32,86,89,91]. 
There is concern that the induction of M2 specific antibodies in the population after large-scale use 
of an M2 based vaccine might increase the selective pressure on this protein, which could drive escape 
from recognition by these antibodies. Although escape mutants were observed after infection of SCID 
mice treated passively with M2 antibodies, the likelihood of the emergence of escape mutants in 
vaccinated mice is low [92]. 
In post-infection sera of humans, antibodies to M2 are virtually absent [93] which indicates that 
these antibodies most likely do not contribute to infection-induced heterosubtypic immunity. Adoptive 
transfer experiments with serum from infected mice confirmed that M2 antibodies did also not 
contribute to heterosubtypic immunity [29].  
5.4. Nucleoprotein 
Upon infection with influenza A virus, also antibodies are induced against other structural proteins 
including the nucleoprotein (NP) [94]. Antibodies against the NP can also be induced by vaccination. 
However, these antibodies are considered non-protective since passive transfer of serum of mice 
vaccinated with recombinant NP vaccines to SCID mice did not protect these mice [95]. In contrast, 
recent studies have shown that rNP immunization reduced morbidity and virus replication after 
influenza virus infection. Furthermore, NP-immune serum transfer to naïve recipient mice conferred 
this protection in an antibody dependent manner [30]. 
It was also demonstrated that the induction of non-neutralizing antibodies including those with 
specificity for NP contributed to heterosubtypic immunity. Although NP specific antibodies cannot 
neutralize influenza virus, indirectly they may contribute to protective immunity by promoting virus-
specific CD8+ T cell responses and the production of VN- antibodies [96]. The formation of immune 
complexes with anti-NP antibodies leading to DC maturation and Th1 cytokine production may also 
contribute to heterosubtypic immunity against influenza [97].  Viruses 2010, 2                                       
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6. Viral targets for the induction of cellular immunity 
6.1. Hemagglutinin and neuraminidase  
The CD4+ T helper cell response after influenza virus infection and vaccination is multi-specific 
and also HA- and NA-specific CD4+ T cells are induced (for review see [98]). CD4+ T cells are 
crucial for the optimal activation and early expansion of B cells, for the initiation and maintenance of 
germinal center reaction and the generation of long-lived plasma and memory B-cells [99-102]. They 
also play a role in the control of virus infection by promoting CD8+ cytotoxic T cell responses   
[103-106].  
Furthermore, it has been suggested that CD4+ T cells also can attack virus-infected host cells 
directly [107]. It is of interest to note that amino acid substitutions have been identified in the HA 
molecule during influenza virus evolution that do not affect recognition by virus-specific antibodies, 
but that are associated with escape from recognition by virus-specific CD4+ T cells [108]. These 
findings suggest that certain T helper cell epitopes of influenza virus are under selective pressure 
similar to those recognized by antibodies [3] or virus-specific CD8+ CTL [109]. On the other hand, it 
has been demonstrated that also more conserved epitopes are located on the HA leading to cross-
reactive T cell responses [110-112]. 
In contrast to CD4+ T cell responses, hardly any virus-specific CD8+ T cells were directed against 
the HA and NA in naturally infected study subjects [111] (see also Table 1). Most likely this is the 
result of intracellular trafficking of HA into the ER, entering the endogenous pathway of antigen 
processing inefficiently. This takes place in the cytosol where other viral proteins are present more 
abundantly. Nevertheless, some epitopes have been identified in HA molecules recognized by virus-
specific human and mouse CD8+ CTL [113-117]. 
6.2. Structural proteins, polymerases and NS proteins 
The virus-specific CD4+ T cell responses after influenza virus infection is directed against a variety 
of proteins, including NP, M1, PB1, PB2, PA and NS1. Also the CD8+ T cell responses are largely 
directed against these proteins and a large number of epitopes have been identified which are 
recognized by virus-specific CD8+ T CTL (Table 1). As shown in Table 1, the number of both CD4+ 
and CD8+ T cell epitopes present on the respective influenza A virus proteins vary. Numbers were 
obtained from the Immune Epitope Database [118,119]. 
The main function of CD8+ T cells is the elimination of virus-infected cells through the release of 
perforin and granzyme or Fas/FasL interaction. In addition, activated CD8+ T cells produce cytokines 
like IFN-γ and TNF-α which can modulate the immune response.  
The majority of CTL epitopes is fully conserved between intra-subtypic variants of influenza A 
viruses. However, it has been demonstrated that some immunodominant CTL epitopes display 
variability that is associated with escape from recognition by specific CTL [109,120-122]. In most 
cases, mutations are fixed during viral evolution, which indicates that these CTL exert selective 
pressure. Indeed, a lower ratio between synonymous and non-synonymous (Ds/Dn) mutations was 
observed in CTL epitopes located in the NP than in the rest of the protein [120]. It was demonstrated 
that naturally occurring mutations in CTL epitopes affected the human in vitro CTL response Viruses 2010, 2                                       
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significantly [123,124]. In contrast, other epitopes are fully conserved, including the HLA-A*0201 
restricted immunodominant epitope from the matrix protein M158-66. Since HLA-A*0201 has a high 
prevalence in the human population, the selective pressure on this epitope must be high. The lack of 
variation in this epitope was explained by functional constraints, since mutations were not tolerated 
without the loss of viral fitness [125,126]. 
Table 1. Human CD8+ and CD4+ T cell epitopes on the influenza A virus. 
Protein   Number of 
MHC Class I 
epitopes 
Number of 
MHC Class II  
epitopes 
HA 6  46 
NA 5  13 
M1 15  31 
M2 2  0 
NP 25  32 
PA 8  2 
PB1 21  5 
PB2 1  1 
NS1 2  1 
NS2 2  0 
The number of CD4+ and CD8+ T cell epitopes were obtained from the 
Immune Epitope Database [119] using the following settings: Source 
organism: Influenza A, Host organism: Homo sapiens, Immune recognition 
context: T cell response and MHC class I/II binding. Multiple epitopes on the 
same location counted as one, all HLA types included.  
 
Many influenza A virus epitopes are also conserved between subtypes, which suggested that virus-
specific CTL play a role in heterosubtypic immunity [127-130]. Indeed, adoptive transfer and 
depletion experiments in mice have demonstrated that CD8+ CTL contribute to protective immunity 
against heterosubtypic strains of influenza A virus [131-136]. Especially when serum antibodies of the 
proper specificity are not present, virus specific CTL may be an important correlate of protection 
against the development of severe disease. Also in humans it was demonstrated that the presence of 
cross-reactive CTL inversely correlated with the extent of viral shedding in the absence of antibodies 
specific for the strain used for experimental infection of the study subjects [34]. Thus, cross-reactive T 
cell responses directed against conserved epitopes after infection may afford some degree of protection 
against influenza viruses of other subtypes. Therefore, the use of conserved proteins like NP and M1 
for the induction of cross-protective CTL responses may be a promising approach for the development 
of “universal” influenza vaccines. For example, the use of live attenuated vaccines, the use of 
adjuvants like ISCOMS that stimulate CD8+ T cell immunity or novel generations of influenza 
vaccines, like viral vector vaccines, may be attractive alternatives [137-141]. Examples of vector 
vaccine production platforms are the recombinant replication deficient adenoviruses, poxviruses and 
Newcastle disease virus vectors, which have been shown to induce protective immunity to influenza Viruses 2010, 2                                       
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viruses efficiently [142-146]. These vaccine candidates facilitate antigen processing and presentation 
by the endogenous route, which is a prerequisite for the efficient induction of CTL responses [147]. 
The induction of cross-reactive CTL responses by natural infections also may have epidemiological 
implications. It was demonstrated that subjects who experienced a prior A/H1N1 infection, less likely 
developed influenza during the A/H2N2 pandemic of 1957 [35]. Furthermore, it is of interest to note 
that especially younger individuals are at risk for severe disease upon total outcomes of H5N1 and new 
H1N1 influenza virus infections [148,149]. Although confounding factors cannot be excluded, younger 
individuals may have been less exposed to seasonal influenza A viruses and consequently have 
developed less CTL immunity than older subjects.  
7. Concluding remarks 
After infection with influenza viruses various arms of the adaptive immune system are activated 
(Figure 1). In Table 2, the viral targets for the induction of protective antibody responses and their 
mode of action are shown.  
Table 2. Viral targets for the induction of protective antibodies. 
Viral 
antigen 
Mode of action  Comments 
HA  Prevents virus attachment to host 
cells 
- Antibodies must have proper specificity 
- strain specific 
NA  Inhibits enzymatic activity of NA 
and spread of virus 
- Antibodies must have proper specificity 
M2  Induction of antibody-dependent 
cell-mediated cytotoxicity (ADCC) 
and elimination of infected cells 
- M2 is highly conserved 
- Hyperimmunization induces cross-protective 
immunity 
NP  Largely unknown, complex 
formation? 
- Non-neutralizing 
- Mode of action and effectiveness unknown 
 
The envelope proteins are the most important targets for the induction of virus-specific antibodies. 
The induction of sufficiently high titers of HA-specific antibodies affords sterilizing immunity against 
infection provided that these antibodies have the proper specificity for the strains causing the infection. 
The induction of NA specific antibodies also contributes to protective immunity, but since these 
antibodies interfere with a late step in the virus replication cycle they cannot prevent infection. 
Furthermore, NA-specific antibodies need to have specificity for the strain causing the infection, like 
HA-specific antibodies. In contrast, M2-specific antibodies induced after hyperimmunization or 
passively administered, afford protection against multiple influenza virus strains and even against 
multiple subtypes of influenza A virus, since this protein is highly conserved. Also M2-specific 
antibodies do not afford sterilizing immunity since their most important mode of action is through 
ADCC after binding to infected cells expressing M2 on their surface. The mode of action and the 
effectiveness of non-neutralizing NP-specific antibodies are not fully understood although it has been 
demonstrated after hyperimmunization that they afford some protection.  Viruses 2010, 2                                       
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Figure 1. Overview of the targets of the immune system for the induction of protective 
immunity against influenza. (A) HA-specific antibodies can bind to the HA on viruses and 
prevent infection of cells. (B) M2e specific antibodies can bind to M2e on virus-infected 
cells and induce antibody-dependent cell-mediated cytotoxicity (ADCC). (C) NA specific 
antibodies inhibit enzymatic activity of NA and thus further spread of newly produced 
virus particles. (D) Pathogens and proteins are broken down into peptides within acidified 
endosomes and these peptides bind to MHC Class II, MHC Class II peptide complexes are 
subsequently transported to the surface of the cell for recognition by CD4+ T cells. (E) 
The mode of action of NP-specific antibodies is largely unknown. (F) Influenza viral 
proteins are degraded in the cytosol of the infected cell by the proteasome into peptides 
that are transported to the endoplasmatic reticulum where they can bind to MHC class I 
molecules. The MHC class I peptide complexes are transported to the surface of the 
infected cells for recognition by CD8+ T cells, which subsequently eliminate the infected 
cell. 
 
 
In addition to the systemic and/or mucosal antibody responses, also virus-specific T cells contribute 
to protective immunity against infection (Table 3). T helper cells, which are directed to virtually all 
viral structural proteins and polymerases, provide the essential signals for the activation and 
differentiation of both B-cell responses and CD8+ T cell responses. In addition, it has been suggested Viruses 2010, 2                                       
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that they are able to attack virus-infected cells directly. The latter function is especially executed by 
virus-specific CTL, which preferentially recognize internal structural proteins like NP and M1. Since 
these proteins are highly conserved between subtypes, CTL responses are cross-reactive and contribute 
to heterosubtypic immunity. 
Table 3. Viral targets for the induction of protective T cell responses. 
Viral antigens  Type of response  Comments 
All viral 
proteins 
CD4+ T helper cell 
response 
- Polarization (Th1/Th2) dependent on antigen  
delivery 
- Essential for B-cell and CD8+ CTL responses 
- Direct action against infected cells 
- HLA restricted 
PB1/PB2/PA/ 
NP/M1/M2/ 
NS1 
CD8+ CTL response  - Key role in elimination of infected cells 
- Cytokine production 
- HLA restriction dictates magnitude of response 
- Only marginal response to HA 
 
In the design and development of vaccines against newly emerging variants of influenza viruses or 
novel pandemic strains, the induction of antibodies directed to the HA (and to a lesser extent, NA) of 
these viruses is preferable. However, the development of such vaccines is time-consuming and 
therefore they cannot always be delivered in a timely fashion. The induction of immunity to conserved 
viral antigens, like antibodies to M2 or cell-mediated immunity to NP or M1, may be an attractive 
approach for the development of more universal vaccines. These could be used as standalone vaccine 
or they may broaden the protective potential of existing vaccines. However, in clinical trials with these 
vaccine candidates, it will be difficult to demonstrate the improved protectiveness of vaccines against 
heterosubtypic strains. Most likely one has to rely on surrogate markers of this type of immunity like 
demonstrating the presence of M2e-specific antibodies and CTL that cross-react with heterosubtypic 
strains of interest in vitro. More research is required to establish that the induction of immunity against 
these conserved antigens is also a correlate of protection in humans. Results obtained so far in animal 
models are promising. 
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